2022 FDA TIDES (Peptides and Oligonucleotides) Harvest
Pharmaceuticals · 22.02.2023 · 16 (3) · 336
DOI: 10.3390/ph16030336 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 22.02.2023. Verfasst von Othman Al Musaimi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation, University of KwaZulu-Natal.
Abstract (Originalsprache)
A total of 37 new drug entities were approved in 2022; although that year registered the lowest number of drug approvals since 2016, the TIDES class consolidated its presence with a total of five authorizations (four peptides and one oligonucleotide). Interestingly, 23 out of 37 drugs were first-in-class and thus received fast-track designation by the FDA in categories such as breakthrough therapy, priority review voucher, orphan drug, accelerated approval, and so on. Here, we analyze the TIDES approved in 2022 on the basis of their chemical structure, medical target, mode of action, administration route, and common adverse effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK.
- Department of Medicinal Chemistry, Evotec (UK) Ltd., Abingdon OX14 4R, UK.
- School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
- CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain.
- KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
ORCID-Profile: Othman Al Musaimi, Danah Al Shaer, Fernando Albericio, Beatriz G de la Torre
Förderung
- National Research Foundation
- University of KwaZulu-Natal
Zitieren
APA
Al Musaimi, O., Al Shaer, D., Albericio, F., & de la Torre, B. G. (2023). 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 16(3), 336. https://doi.org/10.3390/ph16030336
Vancouver
Al Musaimi O, Al Shaer D, Albericio F, de la Torre BG. 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals. 2023;16(3):336. doi:10.3390/ph16030336
BibTeX
@article{AlMusaimi2023,
author = {Al Musaimi, Othman and Al Shaer, Danah and Albericio, Fernando and de la Torre, Beatriz G},
title = {2022 FDA TIDES (Peptides and Oligonucleotides) Harvest},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {3},
pages = {336},
doi = {10.3390/ph16030336}
}
EUVIMED